Top section
Top section
◆ Have capital markets comprehended the heatwave? ◆ Which SSA issuers need to get it done this autumn ◆ Halcyon days for MTN, M&A and ECM bankers
Investors pay little heed to alarming worsening of climate
New $75m partnership to develop treatment for lymphoma was “catalyst for investors”
More articles
More articles
More articles
-
Yellow Cake, a London-listed company operating in the uranium sector, completed a £25.9m share sale on Friday to continue funding uranium purchases from Kazakh uranium producer Kazatomprom. -
The US’s Catalent will buy Paragon Bioservices in a debt and equity financed $1.2bn deal, as consolidation in the gene therapy market builds pace.
-
Chinese smart wearable technology company Huami is issuing new shares through a follow-on American Depositary Shares (ADS) offering of up to $150m.
-
Shares in Stadler Rail, the Swiss maker of rolling stock, gained as much as 12.9% in trading on Friday after it priced its Sfr1.33bn IPO at a discount to its Swiss industrial peers.
-
Hansoh Pharmaceutical Group has refiled its long-anticipated Hong Kong IPO. The Chinese drug maker first planned to go public in 2016, and was said to be readying a roadshow for its IPO as recently as February.
-
Primary EM equity capital markets IPOs are back in vogue, riding the momentum of secondary equity EM indices. With investors clamouring for alpha, Middle Eastern and African IPO issuers are lining up to test the appetite for new deals.
Sub-sections
shared comment list
